{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:26:40Z","timestamp":1789165600128,"version":"build-2803163510"},"reference-count":157,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014\u20132020","award":["grant PI19\/00125"],"award-info":[{"award-number":["grant PI19\/00125"]}]},{"name":"Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014\u20132020","award":["CPII20\/00025"],"award-info":[{"award-number":["CPII20\/00025"]}]},{"name":"Instituto de Salud Carlos III and Fondo Social Europeo 2014\u20132020","award":["grant PI19\/00125"],"award-info":[{"award-number":["grant PI19\/00125"]}]},{"name":"Instituto de Salud Carlos III and Fondo Social Europeo 2014\u20132020","award":["CPII20\/00025"],"award-info":[{"award-number":["CPII20\/00025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is a devastating neurodegenerative disorder that is caused by an abnormal expansion of CAG repeats in the Huntingtin (HTT) gene. Although the main symptomatology is explained by alterations at the level of the central nervous system, predominantly affecting the basal ganglia, a peripheral component of the disease is being increasingly acknowledged. Therefore, the manifestation of the disease is complex and variable among CAG expansion carriers, introducing uncertainty in the appearance of specific signs, age of onset and severity of disease. The monogenic nature of the disorder allows a precise diagnosis, but the use of biomarkers with prognostic value is still needed to achieve clinical management of the patients in an individual manner. In addition, we need tools to evaluate the patient\u2019s response to potential therapeutic approaches. In this review, we provide a succinct summary of the most interesting molecular biomarkers that have been assessed in patients, mostly obtained from body fluids such as cerebrospinal fluid, peripheral blood and saliva.<\/jats:p>","DOI":"10.3390\/ijms23105411","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T21:46:53Z","timestamp":1652392013000},"page":"5411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A Glimpse of Molecular Biomarkers in Huntington\u2019s Disease"],"prefix":"10.3390","volume":"23","author":[{"given":"Silvia","family":"Mart\u00ed-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital General Universitario Dr. Balmis, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-0565","authenticated-orcid":false,"given":"Luis M.","family":"Valor","sequence":"additional","affiliation":[{"name":"Laboratorio de Apoyo a la Investigaci\u00f3n, Hospital General Universitario Dr. Balmis, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The Prevalence of Huntington\u2019s Disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington Disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bpa.12427","article-title":"RNA toxicity induced by expanded CAG repeats in Huntington\u2019s disease","volume":"26","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"B\u00e1\u00f1ez-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I., Guzman, M., Estivill, X., and Mart\u00ed, E. (2012). A Pathogenic Mechanism in Huntington\u2019s Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002481"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Peng, S., Guo, P., Lin, X., An, Y., Sze, K.H., Lau, M.H.Y., Chen, Z.S., Wang, Q., Li, W., and Sun, J.K.-L. (2021). CAG RNAs induce DNA damage and apoptosis by silencing NUDT16 expression in polyglutamine degeneration. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2022940118"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"Hangen","year":"2015","journal-title":"EMBO J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1073\/pnas.1919197117","article-title":"Lack of RAN-mediated toxicity in Huntington\u2019s disease knock-in mice","volume":"117","author":"Yang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.neuron.2015.10.038","article-title":"RAN Translation in Huntington Disease","volume":"88","author":"Ayhan","year":"2015","journal-title":"Neuron"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International Guidelines for the Treatment of Huntington\u2019s Disease","volume":"10","author":"Ferreira","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_12","unstructured":"Bates, G., Harper, P., and Jones, L. (2002). Huntington\u2019s Disease, Oxford University Press. [3rd ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JHD-130082","article-title":"Huntingtin: Here, There, Everywhere!","volume":"2","author":"Sousa","year":"2013","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","article-title":"Huntington\u2019s disease\u2014Neuropathology","volume":"100","author":"Vonsattel","year":"2011","journal-title":"Handb. Clin. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington\u2019s Disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ebiom.2019.09.020","article-title":"A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes","volume":"48","author":"Ciosi","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_17","unstructured":"GeM-HD_Consortium (2019). CAG Repeat Not Polyglutamine Length Determines Timing of Huntington\u2019s Disease Onset. Cell, 178, 887\u2013900.e814."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3233\/JHD-200429","article-title":"The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington\u2019s Disease: A Historical Perspective","volume":"10","author":"Monckton","year":"2021","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.1523\/JNEUROSCI.6223-10.2011","article-title":"The Striatum Is Highly Susceptible to Mitochondrial Oxidative Phosphorylation Dysfunctions","volume":"31","author":"Pickrell","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cortex.2019.04.006","article-title":"\u2018Real-life\u2019 hippocampal-dependent spatial memory impairments in Huntington\u2019s disease","volume":"119","author":"Carmichael","year":"2019","journal-title":"Cortex"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12311-021-01256-5","article-title":"Cerebellar Degeneration Signature in Huntington\u2019s Disease","volume":"20","author":"Diaz","year":"2021","journal-title":"Cerebellum"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/B978-0-12-819973-2.00017-4","article-title":"Hypothalamic pathology in Huntington disease","volume":"182","author":"Aziz","year":"2021","journal-title":"Handb. Clin. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: Widespread pathology in Huntington\u2019s disease","volume":"8","author":"Bjorkqvist","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"603594","DOI":"10.3389\/fimmu.2020.603594","article-title":"Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington\u2019s Disease","volume":"11","author":"Du","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp-2018-318854","article-title":"Platelet abnormalities in Huntington\u2019s disease","volume":"90","author":"Denis","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JHD-130054","article-title":"Cardiac Dysautonomia in Huntington\u2019s Disease","volume":"2","author":"Abildtrup","year":"2013","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/nbdi.1994.0019","article-title":"Huntington\u2019s disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains","volume":"1","author":"Persichetti","year":"1994","journal-title":"Neurobiol. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajhg.2021.12.002","article-title":"Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease","volume":"109","author":"Langbehn","year":"2022","journal-title":"Am. J. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1353-8020(11)70034-7","article-title":"Huntington\u2019s disease: New aspects on phenotype and genotype","volume":"18","author":"Shang","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"GeM-HD_Consortium (2015). Identification of Genetic Factors that Modify Clinical Onset of Huntington\u2019s Disease. Cell, 162, 516\u2013526.","DOI":"10.1016\/j.cell.2015.07.003"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.nicl.2016.10.009","article-title":"Early grey matter changes in structural covariance networks in Huntington\u2019s disease","volume":"12","author":"Coppen","year":"2016","journal-title":"Neuroimage Clin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.18071\/isz.69.0261","article-title":"Gray matter atrophy in presymptomatic Huntington\u2019s patients","volume":"69","author":"Kiraly","year":"2016","journal-title":"Ideggyogyaszati Szemle"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Przybyl, L., Wozna-Wysocka, M., Kozlowska, E., and Fiszer, A. (2021). What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041561"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What Are Biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","article-title":"A Critical Evaluation of Wet Biomarkers for Huntington\u2019s Disease: Current Status and Ways Forward","volume":"7","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-160196","article-title":"Cerebrospinal Fluid Biomarkers for Huntington\u2019s Disease","volume":"5","author":"Byrne","year":"2016","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","article-title":"Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease","volume":"41","author":"Caron","year":"2021","journal-title":"J. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eabc2888","DOI":"10.1126\/scitranslmed.abc2888","article-title":"Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105652","DOI":"10.1016\/j.nbd.2022.105652","article-title":"Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice","volume":"166","author":"Caron","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1172\/JCI64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression","volume":"122","author":"Weiss","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","article-title":"Biofluid Biomarkers in Huntington\u2019s Disease","volume":"1780","author":"Rodrigues","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: A retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","article-title":"Fluid and imaging biomarkers for Huntington\u2019s disease","volume":"97","author":"Zeun","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","article-title":"The many faces of tau","volume":"70","author":"Morris","year":"2011","journal-title":"Neuron"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","article-title":"Tauopathies: New perspectives and challenges","volume":"17","author":"Zhang","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1016\/j.febslet.2006.02.067","article-title":"Tau phosphorylation and aggregation in Alzheimer\u2019s disease pathology","volume":"580","author":"Avila","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","article-title":"Microtubule-associated protein tau in development, degeneration and protection of neurons","volume":"85","author":"Wang","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"ref_54","first-page":"574","article-title":"Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington\u2019s Disease","volume":"13","author":"Lucas","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm.3617","article-title":"Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods","volume":"20","author":"Cabrera","year":"2014","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s007020050095","article-title":"Alzheimer-type lesions in Huntington\u2019s disease","volume":"105","author":"Jellinger","year":"1998","journal-title":"J. Neural Transm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"Turgeon","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JHD-140111","article-title":"The co-occurrence of Alzheimer\u2019s disease and Huntington\u2019s disease: A neuropathological study of 15 elderly Huntington\u2019s disease subjects","volume":"3","author":"Davis","year":"2014","journal-title":"J. Huntingt. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Niemel\u00e4, V., Landtblom, A.-M., Blennow, K., and Sundblom, J. (2017). Tau or neurofilament light\u2014Which is the more suitable biomarker for Huntington\u2019s disease?. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172762"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/WCO.0b013e3283168d1d","article-title":"The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"21","author":"Mackenzie","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"ref_64","first-page":"86","article-title":"TDP-43 proteinopathies: A new wave of neurodegenerative diseases","volume":"92","author":"Orie","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_65","first-page":"1","article-title":"Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration","volume":"17","author":"Irwin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuron.2020.11.005","article-title":"Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis","volume":"109","author":"Dewan","year":"2020","journal-title":"Neuron"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sampedro, F., Mart\u00ednez-Horta, S., P\u00e9rez-P\u00e9rez, J., P\u00e9rez-Gonz\u00e1lez, R., Horta-Barba, A., Campolongo, A., Izquierdo, C., Aracil-Bola\u00f1os, I., Rivas, E., and Puig-Davi, A. (2022). Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington\u2019s Disease. Clin. Neuroradiol., 1\u20139. Online ahead of print.","DOI":"10.1007\/s00062-022-01150-5"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/mds.28686","article-title":"The Emerging Role of Phosphodiesterases in Movement Disorders","volume":"36","author":"Erro","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington\u2019s disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_71","first-page":"1","article-title":"Early alteration of epigenetic-related transcription in Huntington\u2019s disease mouse models","volume":"8","author":"Guiretti","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nn.4256","article-title":"Integrated genomics and proteomics define huntingtin CAG length\u2013dependent networks in mice","volume":"19","author":"Langfelder","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2032s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ajhg.2016.03.015","article-title":"Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy","volume":"98","author":"Diggle","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ajhg.2016.02.015","article-title":"De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions","volume":"98","author":"Mencacci","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/mds.27963","article-title":"PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington\u2019s Disease Progression","volume":"35","author":"Fazio","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jns.2016.07.033","article-title":"Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington\u2019s disease gene carriers","volume":"368","author":"Wilson","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","article-title":"BDNF signaling in context: From synaptic regulation to psychiatric disorders","volume":"185","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E.J., Sassone, J., and Ciammola, A. (2011). Brain-Derived Neurotrophic Factor in Patients with Huntington\u2019s Disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022966"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","article-title":"Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes","volume":"35","author":"Zuccato","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajmg.b.30501","article-title":"Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients","volume":"144","author":"Ciammola","year":"2007","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_86","first-page":"71","article-title":"A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington\u2019s disease: Looking for biomarkers","volume":"45","author":"Zielonka","year":"2012","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnmol.2019.00335","article-title":"Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington\u2019s Disease Patients","volume":"12","author":"Gutierrez","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/s41598-021-83000-x","article-title":"Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington\u2019s disease","volume":"11","author":"Ou","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_89","first-page":"27","article-title":"Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington\u2019s Disease: Relationships with Social Cognition Symptoms","volume":"156","author":"Betti","year":"2018","journal-title":"Arch. Ital. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: A stressful review","volume":"55","author":"Reichmann","year":"2015","journal-title":"Neuropeptides"},{"key":"ref_91","first-page":"1","article-title":"Neuroprotective effects of neuropeptide Y against neurodegenerative disease","volume":"19","author":"Pain","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0006-8993(85)90921-7","article-title":"Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington\u2019s disease","volume":"340","author":"Dawbarn","year":"1985","journal-title":"Brain Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.410410418","article-title":"Cortical peptide changes in Huntington\u2019s disease may be independent of striatal degeneration","volume":"41","author":"Mazurek","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrn2216","article-title":"The effect of neurodegenerative diseases on the subventricular zone","volume":"8","author":"Curtis","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jnc.13624","article-title":"Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington\u2019s Disease: Increased NPY levels and differential degradation of the NPY1-30 fragment","volume":"137","author":"Wagner","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","article-title":"Uric Acid as a CNS Antioxidant","volume":"19","author":"Bowman","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11910-012-0282-7","article-title":"Urate in Parkinson\u2019s Disease: More than a Biomarker?","volume":"12","author":"Chen","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2020.00073","article-title":"Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington\u2019s Patients","volume":"14","author":"Haque","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cns.13768","article-title":"Kynurenic acid in neurodegenerative disorders\u2014unique neuroprotection or double-edged sword?","volume":"28","author":"Ostapiuk","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jnc.15360","article-title":"Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington\u2019s disease","volume":"158","author":"Rodrigues","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2011.07.001","article-title":"What have we learned from gene expression profiles in Huntington\u2019s disease?","volume":"45","author":"Seredenina","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","article-title":"Transcription, Epigenetics and Ameliorative Strategies in Huntington\u2019s Disease: A Genome-Wide Perspective","volume":"51","author":"Valor","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"ref_104","first-page":"105155","article-title":"Epigenetic mechanisms underlying enhancer modulation of neuronal identity, neuronal activity and neurodegeneration","volume":"147","author":"Awada","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.neuron.2020.06.021","article-title":"Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation","volume":"107","author":"Lee","year":"2020","journal-title":"Neuron"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2050-7771-1-28","article-title":"Whole gene expression profile in blood reveals multiple pathways deregulation in R6\/2 mouse model","volume":"1","author":"Diamanti","year":"2013","journal-title":"Biomark. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","article-title":"Gene expression in Huntington\u2019s disease skeletal muscle: A potential biomarker","volume":"14","author":"Strand","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","article-title":"Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: Parallel changes in muscle and brain","volume":"11","author":"Hanson","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.0504921102","article-title":"Genome-wide expression profiling of human blood reveals biomarkers for Huntington\u2019s disease","volume":"102","author":"Borovecki","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1073\/pnas.0703652104","article-title":"Analysis of potential transcriptomic biomarkers for Huntington\u2019s disease in peripheral blood","volume":"104","author":"Runne","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1073\/pnas.1104409108","article-title":"Transcriptional modulator H2A histone family, member Y ( H2AFY ) marks Huntington disease activity in man and mouse","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jns.2013.11.014","article-title":"Gene expression profile in fibroblasts of Huntington\u2019s disease patients and controls","volume":"337","author":"Marchina","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/ejhg.2014.281","article-title":"Huntington\u2019s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood","volume":"23","author":"Mastrokolias","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1177\/147323001003800510","article-title":"ADP-Ribosylation Factor Guanine Nucleotide-Exchange Factor 2 (ARFGEF2): A New Potential Biomarker in Huntington\u2019s Disease","volume":"38","author":"Lovrecic","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/mds.22477","article-title":"Gene expression changes in blood as a putative biomarker for Huntington\u2019s disease","volume":"24","author":"Lovrecic","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"fcaa172","DOI":"10.1093\/braincomms\/fcaa172","article-title":"Longitudinal expression changes are weak correlates of disease progression in Huntington\u2019s disease","volume":"2","author":"Mitchell","year":"2020","journal-title":"Brain Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/omi.2017.0206","article-title":"Transcriptomic Biomarkers for Huntington\u2019s Disease: Are Gene Expression Signatures in Whole Blood Reliable Biomarkers?","volume":"22","author":"Zadel","year":"2018","journal-title":"OMICS J. Integr. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"44849","DOI":"10.1038\/srep44849","article-title":"Huntington\u2019s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer\u2019s disease","volume":"7","author":"Moss","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"573560","DOI":"10.3389\/fneur.2020.573560","article-title":"RNA Sequencing of Human Peripheral Blood Cells Indicates Upregulation of Immune-Related Genes in Huntington\u2019s Disease","volume":"11","author":"Spruth","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Colpo, G.D., Rocha, N.P., Furr Stimming, E., and Teixeira, A.L. (2020). Gene Expression Profiling in Huntington\u2019s Disease: Does Comorbidity with Depressive Symptoms Matter?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228474"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/13518","article-title":"Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_122","first-page":"2893","article-title":"RNA-Seq of Huntington\u2019s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation","volume":"25","author":"Miller","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_123","first-page":"388","article-title":"Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models","volume":"73","author":"Andre","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Valor, L., Morales, J., Herv\u00e1s-Corpi\u00f3n, I., and Mar\u00edn, R. (2021). Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168368"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","article-title":"The MicroRNA Spectrum in 12 Body Fluids","volume":"56","author":"Weber","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/ATVBAHA.112.300139","article-title":"Intercellular Transport of MicroRNAs","volume":"33","author":"Boon","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/mds.26457","article-title":"Study of plasma-derived miRNAs mimic differences in Huntington\u2019s disease brain","volume":"30","author":"Hoss","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","article-title":"Circulating microRNAs in Huntington\u2019s disease: Emerging mediators in metabolic impairment","volume":"108","author":"Crespo","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e1800619","DOI":"10.1002\/mnfr.201800619","article-title":"Customized Dietary Intervention Avoids Unintentional Weight Loss and Modulates Circulating miRNAs Footprint in Huntington\u2019s Disease","volume":"62","author":"Aganzo","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"657973","DOI":"10.3389\/fneur.2021.657973","article-title":"Circulating hsa-miR-323b-3p in Huntington\u2019s Disease: A Pilot Study","volume":"12","author":"Ferraldeschi","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","article-title":"Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease","volume":"20","author":"Gaughwin","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0475-2","article-title":"Common disease signatures from gene expression analysis in Huntington\u2019s disease human blood and brain","volume":"11","author":"Mina","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic Profiling of Plasma in Huntington\u2019s Disease Reveals Neuroinflammatory Activation and Biomarker Candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Wild, E., Magnusson-Lind, A., Lahiri, N., Krus, U., Orth, M.J., Tabrizi, S., and Bj\u00f6rkqvist, M. (2011). Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr., 3.","DOI":"10.1371\/currents.RRN1231"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fphys.2017.00127","article-title":"Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington\u2019s Disease Mouse Model","volume":"8","author":"Mielcarek","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.archoralbio.2011.10.015","article-title":"Determination of leucocyte subsets in human saliva by flow cytometry","volume":"57","author":"Juras","year":"2012","journal-title":"Arch. Oral Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.1038\/s41598-018-25311-0","article-title":"Quantitation of the cellular content of saliva and buccal swab samples","volume":"8","author":"Theda","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bj.2018.03.004","article-title":"Salivary biomarkers for the diagnosis and monitoring of neurological diseases","volume":"41","author":"Farah","year":"2018","journal-title":"Biomed. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.psyneuen.2012.10.020","article-title":"Cortisol and depression in pre-diagnosed and early stage Huntington\u2019s disease","volume":"38","author":"Shirbin","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-012-6732-y","article-title":"The relationship between cortisol and verbal memory in the early stages of Huntington\u2019s disease","volume":"260","author":"Shirbin","year":"2012","journal-title":"J. Neurol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jne.12255","article-title":"Hypothalamic-Pituitary-Adrenal Axis Functioning in Huntington\u2019s Disease and its Association with Depressive Symptoms and Suicidality","volume":"27","author":"Hubers","year":"2015","journal-title":"J. Neuroendocr."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1038\/s41598-018-25095-3","article-title":"Salivary levels of total huntingtin are elevated in Huntington\u2019s disease patients","volume":"8","author":"Haque","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","article-title":"Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease","volume":"104","author":"Wright","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1073\/pnas.98.4.1811","article-title":"The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington\u2019s disease pathogenesis","volume":"98","author":"Holbert","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10048-005-0023-z","article-title":"The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington\u2019s disease","volume":"7","author":"Metzger","year":"2005","journal-title":"Neurogenetics"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Saft, C., Epplen, J.T., Wieczorek, S., Landwehrmeyer, G.B., Roos, R.A., De Yebenes, J.G., Dose, M., Tabrizi, S., Craufurd, D., and Arning, L. (2011). NMDA receptor gene variations as modifiers in Huntington disease: A replication study. PLoS Curr., 3.","DOI":"10.1371\/currents.RRN1247"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Valc\u00e1rcel-Ocete, L., Alkorta-Aranburu, G., Iriondo, M., Fullaondo, A., Garc\u00eda-Barcina, M., Fern\u00e1ndez-Garc\u00eda, J.M., Lezcano-Garc\u00eda, E., Losada-Domingo, J.M., Ruiz-Ojeda, J., and De Arcaya, A. (2015). Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131573"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/hmg\/ddx286","article-title":"A modifier of Huntington\u2019s disease onset at the MLH1 locus","volume":"26","author":"Lee","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28896","article-title":"A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis","volume":"37","author":"Lee","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Lee, J.-M., Huang, Y., Orth, M., Gillis, T., Siciliano, J., Hong, E., Mysore, J.S., Lucente, D., Wheeler, V.C., and Seong, I.S. (2022). Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. Am. J. Hum. Genet.","DOI":"10.1016\/j.ajhg.2022.03.004"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41593-022-01033-5","article-title":"Exome sequencing of individuals with Huntington\u2019s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset","volume":"25","author":"McAllister","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"64674","DOI":"10.7554\/eLife.64674","article-title":"Propensity for somatic expansion increases over the course of life in Huntington disease","volume":"10","author":"Kacher","year":"2021","journal-title":"eLife"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/brain\/awz115","article-title":"MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1","volume":"142","author":"Flower","year":"2019","journal-title":"Brain"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JHD-200002","article-title":"Huntington\u2019s Disease Clinical Trials Corner: April 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington\u2019s Disease Models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:57Z","timestamp":1760137797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":157,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105411"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105411","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}